Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) generates frequent news as a global eye care company listed on the SIX Swiss Exchange and the New York Stock Exchange. Company communications emphasize a long heritage in eye care, a broad Surgical and Vision Care portfolio, and a large international patient reach, which together make Alcon a regular subject of healthcare, medical device and capital markets coverage.
News about Alcon often highlights developments in its Surgical and Vision Care segments, including product launches and portfolio updates that address conditions such as cataracts, glaucoma, retinal diseases and refractive errors. The company has stated that it is advancing global launches of major products across these franchises, and such initiatives are typically announced through press releases and investor events.
Investors following ALC news can also expect updates on corporate strategy and transactions. For example, Alcon has reported on a definitive merger agreement with STAAR Surgical Company and later announced the termination of that agreement in a January 6, 2026 press release. These items appear in both company news and related regulatory filings, providing insight into how Alcon approaches acquisitions and refractive surgery strategy.
Coverage may further include Alcon’s participation in major healthcare conferences, where senior executives present the company’s outlook and discuss its Surgical and Vision Care businesses. Such events are typically accompanied by webcasts and formal announcements. By monitoring this news feed, readers can track key developments affecting Alcon’s product portfolio, strategic direction and presence in the global eye care market.
Alcon (SIX/NYSE: ALC) announced that CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 8:15 a.m. PST. A live webcast will be available at investor.alcon.com/news-and-events/events-and-presentations.
Alcon describes itself as the global leader in eye care with a heritage of over 75 years, serving more than 260 million people across 140 countries and employing over 25,000 associates. The release includes investor and media contact details for Geneva and Fort Worth offices.
Broadwood Partners, which owns 30.2% of STAAR common stock, criticized STAAR Surgical’s fourth postponement of the shareholder vote on the proposed sale to Alcon (NYSE: ALC).
The Special Meeting was rescheduled from December 19, 2025 to January 6, 2026. Broadwood called the transaction ill-advised, urged shareholders to vote AGAINST the deal, and said several large shareholders, all three proxy advisory firms, and at least one director have expressed skepticism about the process, timing, and price.
Alcon (SIX/NYSE: ALC) has exercised its right under the merger agreement to require STAAR Surgical (NASDAQ: STAA) to adjourn its Special Meeting of Stockholders.
The Special Meeting originally set for December 19, 2025 at 8:30 a.m. Pacific Time is adjourned to January 6, 2026 at 8:30 a.m. Eastern Time. The record date for eligible STAAR stockholders remains the close of business on October 24, 2025. Stockholders with voting questions should contact STAAR's proxy solicitor, Innisfree M&A Incorporated, using the provided phone numbers for stockholders and intermediaries.
Defender Capital (long‑term STAAR shareholder, ~1.5% stake) reiterated it will vote AGAINST STAAR Surgical's proposed sale to Alcon (NYSE: ALC) and criticized the board's pursuit of the transaction. Defender called the timing and price “wrong,” noted stabilization in Q2 results, cited Broadwood Partners' engagement, and highlighted governance concerns after the company delayed the shareholder vote to December 19 and reopened bidding.
Broadwood Partners (major shareholder) sent an open letter to the STAAR Surgical board urging fellow shareholders to vote AGAINST the proposed sale to Alcon (NYSE: ALC) ahead of the special meeting scheduled for December 17, 2025. Broadwood says it owns 30.2% of STAAR, believes the deal materially undervalues the company, and pledges to cooperate with the board if the transaction fails.
Key points: Broadwood projects a path to $50 per share next year if STAAR remains independent, cites inventories normalizing in China and upcoming product launches, and calls for board leadership changes to restore shareholder confidence.
Summary not available.
Yunqi Capital, a 5.1% shareholder of STAAR (NASDAQ: STAA), urged shareholders on December 17, 2025 to reject Alcon’s amended acquisition offer of $30.75 and back STAAR’s standalone trajectory.
Yunqi said proxy adviser Glass Lewis continues to oppose the merger while ISS flipped in favor but noted shareholders could reasonably remain opposed. Yunqi criticized STAAR’s go-shop process (company engaged with 21 third parties) and highlighted upcoming catalysts including a January 2026 launch of EVO ICL V5, which the firm says could carry a 30–70% premium to existing ICL pricing.
STAAR Surgical (NASDAQ:STAA) announced that independent analysts and proxy advisor ISS view the amended Alcon (SIX/NYSE:ALC) merger as providing value to STAAR stockholders. Under the revised agreement dated December 9, 2025, STAAR stockholders would receive $30.75 per share in cash, equal to a 74% premium to STAAR's 90-day VWAP as of August 4, 2025 and a 66% premium to the August 4 closing price.
Analysts cited a ~$1.6bn all-in valuation (~4.5x forward EV/Sales using blended 2026–2027 estimates of $271m and $300m) and noted limited competing bids after the go-shop. ISS updated its report to recommend shareholders vote FOR. A virtual Special Meeting is set for December 19, 2025.
Summary not available.
Summary not available.